Investigation of time course of changes in the concentrations of angiogenic factors on the length of physiological pregnancy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To determine the serum concentrations of vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and soluble VEGF receptor 1 (sVEGF-R1) in pregnant women with physiological pregnancy. Subjects and methods. A prospective cohort study was conducted in 114 women with physiological pregnancy. The factors were controlled at 11-13, 22-24, and 32-34 weeks’ gestation. The levels of VEGF was determined by an enzyme immunoassay and those of sVEGF-R1 by an electrochemiluminiscence immunoassay. Results. There was a rise in the concentration of PlGF with longer gestation. The level of PlGF was 51.9±7.2 and 481.3±27.3 pg/ml at 11-13 and 32-34 weeks’ gestation, respectively. That of VEGF increased from the first to the second trimester of pregnancy and decreased by 32-34 weeks’ gestation. The concentration of sVEGF-R1 remained relatively stable in the first and the second trimester of pregnancy (1991.6±30.7and 1980.7±27.7 pg/ml, respectively). At 32-34 weeks’ gestation, there was an increase in the indicator up to 2266.5±51.3pg/ml. Conclusion. The findings demonstrate the process of physiological angiogenesis and the investigation used in our descriptive study should be regarded as a diagnostic procedure in the examination of women at risk for vascular events.

Full Text

Restricted Access

About the authors

N. Yu Yakovleva

V.A. Almazov North-West Federal Medical Research Center, Ministry of Health of Russia

Email: Natalis.1986@mail.ru
MD, researcher of scientific research laboratory of physiology and pathology of pregnancy and delivery

E. Yu Vasilyeva

V.A. Almazov North-West Federal Medical Research Center, Ministry of Health of Russia

Email: elena-almazlab@yandex.ru
MD, head of central diagnostic laboratory

E. S Shelepova

V.A. Almazov North-West Federal Medical Research Center, Ministry of Health of Russia

Email: garbunchik@mail.ru
MD, researcher of scientific research laboratory of reproduction and women health

N. R Ryabokon

V.A. Almazov North-West Federal Medical Research Center, Ministry of Health of Russia

Email: n-i-k-o-n@mail.ru
MD, Teaching Assistant, chair of Obstetrics and Gynecology

E. L Khazova

V.A. Almazov North-West Federal Medical Research Center, Ministry of Health of Russia

Email: kamishi77@mail.ru
MD, researcher of scientific research laboratory of reproduction and women health

K. R Buravleva

Obstetrics and Gynecology

Email: k_senia9l@mail.ru
resident of chair

L. V Kuznetsova

V.A. Almazov North-West Federal Medical Research Center

Email: krivo73@mail.ru
MD, PhD, assistant professor of chair of Obstetrics and Gynecology

I. E Zazerskaya

V.A. Almazov North-West Federal Medical Research Center

Email: zazera@mail.ru
MD, PhD, head of chair of Obstetrics and Gynecology

References

  1. Соколов Д.И. Васкулогенез и ангиогенез в развитии плаценты. Журнал акушерства и женских болезней. 2007; 56(3): 129-33. [Sokolov D.I. Angiogenesis and vasculogenesis in development of the placenta. Journal akusherstva i jenskih boleznei/Journal of Obstetrics and gynecological diseases. 2007; 56 (3): 129-133. (in Russian)]
  2. Ходжаева З.С., Мусиенко Е.В., Сухих Г.Т. Особенности секреции про- и антиангиогенных факторов в I триместре беременности у женщин с привычным выкидышем в анамнезе. Проблемы репродукции. 2011; 2: 30-4. [Khodzaeva Z.S., Musienko E.V., Sukhikh G.T. Features secretion of pro- and anti-angiogenic factors in the I trimester of pregnancy in women with recurrent miscarriage history. Problemi reprodukcii/Problems of reproduction. 2011; 2: 30-34. (in Russian)]
  3. Charnock-Jones D.S., Kaufmann P., Mayhew T.M. Aspects of human fetoplacental vasculogenesis and angiogenesis. Molecular regulation. Placenta. 2004; 25(2-3): 103-13.
  4. Бурлев В.А., Ильясова Н.А., Саркисов С.Э. Содержание ангиогенных факторов в крови у больных с эндометриальной гиперплазией. Проблемы репродукции. 2011; 6: 18-25. [Burlev V.A., Ilyasov N.A., Sarkisov S.E. Angiogenic factors content in the blood of patients with endometrial hyperplasia. Problemi reprodukcii/Problems of reproduction. 2011; 6: 18-25. (in Russian)]
  5. Andraweera P.H., Dekker. G.A., Roberts C.T. The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum. Reprod. Update. 2012; 18(4): 436-57.
  6. Никитина Л.А., Демидова Е.И., Радзинский В.Е., Демидов Б.С., Самоходская Л.М. Роль матриксных белков, цитокинов и факторов ангиогенеза маточно-плацентарного комплекса в регуляции имплантации и плацентации. Акушерство и гинекология. 2007; 3: 5-10. [Nikitina L.A., Demidova E.I., Radzinsky V.E., Demidov B.S., Samokhodskaya L.M. Role of matrix proteins, cytokines and angiogenic factors uteroplacental complex regulation of implantation and placentation. Akusherstvo i ginekologiya/Obstetrics and gynecology. 2007; (3): 5-10. (in Russian)]
  7. Clark D.E., Smith S.K., He Y., Day K.A., Licence D.R., Corps A.N. et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol. Reprod. 1998; 59(6): 1540-8.
  8. Koch S., Tugues S., Li X., Ponten A., Thoren P. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011; 437(2): 169-83.
  9. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004; 350(7): 672-83.
  10. Verlohren S., Herraiz I., Lapair O., Schlembach D., Zeisler H., Calda P. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014; 63(2): 346-52.
  11. Palm М., Basu S., Larsson A., Wernroth L., A'Kerud H., Akelsson O. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. Acta Obstet. Gynecol. Scand. 2011; 90(11): 1244-51.
  12. Сидорова И.С., Никитина Н.А. Особенности патогенеза эндотелиоза при преэклампсии. Акушерство и гинекология. 2015; 1: 72-8. [Sidorova I.S., Nikitina N.A. Pathogenesis of endotheliosis in preeclampsia. Akusherstvo i ginekologiya/Obstetrics and gynecology. 2015; (1): 72-8. (in Russian)]
  13. Зиганшина М.М., Кречетова Л.В., Ванько Л.В., Ходжаева З.С., Мусиенко Е.В., Сухих Г.Т. Про- и антиангиогенные факторы в патогенезе ранних потерь беременности. Часть 1. Особенности содержания про- и антиангиогенных сывороточных факторов в ранние сроки беременности. Акушерство и гинекология. 2012; 3: 14-9. [Ziganshina M.M., Krechetova L. V., Vanko L. V., Khodzhayeva Z.S., Musiyenko E.V., Sukhikh G.T. Pro- and antiangiogenic factors in the pathogenesis of early pregnancy losses. Part 1.The specific features of pro- and antiangiogenic serum factors in early pregnancy. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2012; (3): 14-9. (in Russian)]
  14. Johnson P.M., Christmas S.E., Vince G.S. Immunological aspects of implantation and implantation failure. Hum. Reprod. 1999; 14(Suppl.2): 26-36.
  15. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219(4587): 983-5.
  16. Ziche M., Maglione D., Ribatti D., Morbidelli L. Placenta growth factor-1 is chemotactic, mitogenic and angiogenic. Lab. Invest. 1997; 76(4): 517-31.
  17. Yonekura H., Sakurai S., Liu X., Migita H., Wang H., Yamagishi S. et al. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J. Biol. Chem. 1999; 274(49): 35172-8.
  18. Wikstrom A.K., Larsson A., Eriksson U.J., Nash P., Norden-Lindeberg S., Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet. Gynecol. 2007; 109(6): 1368-74.
  19. Taylor R.N., Grimwood J., Taylor R.S., McMaster M.T., Fisher S.J., North R.A. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am. J. Obstet. Gynecol. 2003; 188(1): 177-82.
  20. Schiettecatte J., Russcher H., Anckaert E., Mees M., Leeser B., Tirelli A.S. et al. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin. Biochem. 2010; 43(9): 768-70.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies